the low peripheral vascular resistance, low arterial pressure and increased cutaneous blood flow often found in such patients. '7-2' We propose that, in cirrhosis, chronicallyimpaired, hepatic inactivation of methionine enkephalin and possibly other small opioid peptides, may cause or contribute to vasodilatation and that one important consequence may be the development of ascites, arising largely as a result of an imperfect homeostatic attempt to maintain systemic arterial pressure. Thus, the sodium and water retention of ascites may be mediated largely by secondary activation of the sympathetic nervous system and adrenal medullae. A similar mechanism may stimulate the non-osmotic release of vasopressin. Opioid peptide initiated lymphatic leakage may also contribute to ascites formation. This hypothesis is outlined in Figure 1 and discussed in more detail below.
Methods

SUBJECTS
As an initial investigation of this hypothesis, we studied 50 patients with biopsy proven cirrhosis of the liver. Half of these patients had ascites, with or without peripheral oedema (group I). The ascites was unequivocally present on clinical examination, confirmed and shown to be free of infection by diagnostic aspiration. The remaining 25 15 disease controls (three congestive be necessary to prevent methionine enkephalin cardiac failure, three chronic asthma, three chronic degradation in plasma7 and these inhibitors are pancreatitis, two untreated coeliac disease, two expensive. As an aminopeptidase which inactivates insulin-dependent diabetes mellitus, one chronic enkephalins is denatured by a pH below 5.5,`2 we intestinal pseudo-obstruction, one pneumococcal developed a technique using immediate chilling of pneumonia complicating carcinoma of the bronchus) the sample and its acidification to pH 5.0-5.5 using who had normal bilirubin and alanine aminotrans-citric acid. This procedure was shown to preserve ferase and no other evidence of liver disease (group more than 90% of methionine enkephalin for at least III) and with 15 healthy controls (group IV). In one hour. Addition of larger enkephalins containing addition, three further subjects with cirrhosis were the methionine enkephalin sequence (methionine studied before and after the development of ascites. enkephalin arg-phe, methionine enkephalin argAll the subjects with ascites were hospital inpatients gly-leu, peptide E) to chilled, citric acid containand taking a sodium restricted diet of approximately ing plasma samples did not result in increased 40 mmol/day. None of the subjects were taking any methionine enkephalin values when measured by drugs which are known or likely to affect plasma either the radioimmunoassay or high performance methionine enkephalin or catecholamines. In par-liquid chromatography, indicating that acidification ticular, no subject was taking B-adrenergic blockers. does not promote and may prevent processing of Subjects were excluded from the study for the larger enkephalins to methionine enkephalin. following reasons: (1) the presence of ascites was Further acidification of the plasma sample to pH equivocal. (2) They had had a previous episode of 3.0-4.0 and storage at -70°C was shown to maintain ascites and still required diuretics to maintain them methionine enkephalin for over a year. free frpm further fluid retention. (3) They had a plasma creatinine greater than the upper limit of Radioimmunoassay normal for our laboratory. (4) They had had a Methionine enkephalin was partially separated from gastrointestinal bleed within the previous five days. other plasma constituents using C18 Sep-Pak (5) They had been drinking alcohol within the columns primed with methanol and water. One previous three weeks.
millilitre of the sample was added to the columns Pulse rate and arterial pressure were measured just which were then rinsed with 4% acetic acid and before blood sampling. eluted using methanol. The dried eluate was reconstituted with bovine serum albumin-phosphate buffer Sample collection and 200 pl was assayed in duplicate. 100 pl of Venous blood was collected with the subjects at rest 1`25-methionine enkephalin was mixed with the in a sitting position, a heparinised cannula having sample, standard and non-specific binding tubes and been inserted 20 minutes earlier. The samples for incubated for 17 hours at 4°C. One hundred micromethionine enkephalin measurement were collected lites of rabbit gamma globluin carrier was then using chilled syringes and chilled bottles containing added, followed by 500 R1 saturated ammonium citric acid. They were transferred rapidly to a pre-sulphate to separate bound from free tracer. After standing for 20 minutes, the tubes were centrifuged at 1000 g for 10 minutes and the supernatant decanted. The radioactivity of the precipitate was counted in a gamma scintillation counter for five minutes. The percentage of bound tracer divided by the tracer's total counts was calculated for each sample and the quantity of methionine enkephalin determined by reference to the standard curve. The antibody, tracer, and reagents were purchased from Immuno Nuclear Corporation, Stillwater, Minnesota, USA.
Our validation studies on the assay showed parallelism, when either pure methionine enkephalin or plasma samples containing high quantities of the peptide were serially diluted. We found a recovery rate of 86% and within-and between-assay coefficients of variation of 8% and 11% respectively. Nonspecific binding ranged from 6*5-7.9%. Minimum sensitivity was 50 pmol/l (30 pg/ml). Using pure peptides purchased from either Bachem Inc or Peninsula Laboratories, the antibody was shown to 900- be highly specific for methionine enkephalin. Its cross reactivity was: leucine enkephalin 5%, methionine enkephalin-arg-phe 3%, gly-gly-phe-met 2%, and methionine enkephalin-arg-gly-leu, dynorphin 
Results
Plasma methionine enkephalin was invariably raised in the patients with ascites (Fig. 2) , with a range of 2.5 to 13.7 times the upper limit of normal. Its median value in the ascites patients was 4.6 to 6-9 times the median values in the other three groups (Table) . There was no significant difference in methionine enkephalin between the 18 patients who were taking spironolactone, median 390 pmolIl, range 235-1315 (223 pg/ml, 135-755) and the seven who were not, median 495 pmol/l, range 260-880 (284 pg/ml, 150-505). In three further patients with cirrhosis who developed ascites during the study, methionine enkephalin rose in all of them from 80, 95, and 175 pmolIl to 470, 255, and 660 pmol/l respectively (45, 55, and 100 pg/ml to 270, 145, and 380 pg/ml).
In the patients with ascites, the median value of noradrenaline was increased 2.5 to 4.2 times and median adrenaline concentration 1.8 to 2.5 times that of the remaining groups (Table) . The patients with ascites also had a lower plasma albumin and higher plasma creatinine compared with the other groups. Conversion factors: pmol/l to pg/ml: methionine enkephalinx0-574, noradrenaline 0-170, adrenaline 0-184.
In the 50 patients with cirrhosis (groups I and II), methionine enkephalin was directly correlated with noradrenaline (r=0.359, p<0.01), adrenaline (r=0.491, p<0.001), and creatinine (r=0.331, p<002). In addition, noradrenaline directly correlated with adrenaline (r=0.381, p<0.01) and creatinine (r=0.323, p<002). Methionine enkephalin (r= -0-434, p<0-002), noradrenaline (r=-0-655, p<0-001), and adrenaline (r=-0*457, p<O-OOl) were all inversely correlated with plasma albumin.
There were no significant differences between the four groups of subjects in either sex distribution or age.
Discussion
This study shows that methionine enkephalin is increased considerably in the plasma of patients with hepatic cirrhosis and ascites. This finding cannot be explained by these patients being more ill than the remainder, as most were chronically rather than acutely unwell, and apparently no more so than those patients in the disease control group. Furthermore, some of the relatively well subjects with cirrhosis without ascites also had moderately raised plasma methionine enkephalin. Acute blood loss causes release of this opioid peptide from the adrenal glands.2728 All the subjects with cirrhosis, however, were haemodynamically stable.
The source(s) of circulating methionine enkephalin is unclear. It can be released by the adrenal glands3 and is present in sympathetic nerves32 and the gut.33 Bilateral adrenalectomy has no effect on the normal concentration of methionine containing enkephalins,34 however, and we have found markedly raised plasma methionine enkephalin in the presence of normal sympathetic tone in patients with acute liver disease. 35 Beta-endorphin, a much larger opioid peptide whose plasma concentration, like methionine enkephalin,27 28 rises in response to acute hypovolaemaemia,j'37 is not increased in patients with cirrhosis and ascites.' This suggests that the rise in plasma methionine enkephalin is not a non-specific response to vascular underfilling in these patients. The data clearly do not permit a definite conclusion, however, as to whether the increase in plasma methionine enkephalin in the patients with ascites is caused by increased secretion, diminished hepatic inactivation or both.
Like opiates," opioid peptides are potent vasodilators'2-'6 and receptor sites for methionine enkephalin include splanchnic blood vessels.9Ẁ e propose that increased plasma methionine enkephalin and possibly other small opioid peptides may cause or contribute to vasodilatation and thereby initiate increased sympathetic tone (indicated by raised plasma noradrenaline,3;14) adrenaline secretion, and non-osmotic vasopressin release42 in a homeostatic attempt to maintain systemic arterial pressure.
Evidence that vasodilatation may initiate raised plasma catecholamines and ascites formation was provided by a recent study in which patients with refractory ascites had their ascitic fluid recirculated into their vascular compartment by peritoneovenous shunting.43 This procedure produced a marked natriuresis and diuresis, and a return of raised plasma catecholamines to normal. Despite these changes, the patients remained hypotensive with a low peripheral vascular resistance.
Raised plasma catecholamines in cirrhosis are a consequence of increased secretion rather than diminished clearance."45 In decompensated cirrhosis, increased renal artery resistance reduces renal blood flow, and intrarenal haemodynamics are deranged.' Catecholamines are capable of causing such perturbations in renal perfusion47-and may, thereby, promote sodium and water retention in decompensated cirrhosis.505' Leakage of lymph from the hepatic lymphatics into the peritoneum may contribute to ascites formation.52 Histamine, even in low doses, increases hepatic lymph flow and its protein content by enhancing the permeability of the endothelial cells lining the sinusoids.53 As opioid peptides stimulate histamine release,5" it is possible that they may also promote ascites by permitting egress of hepatic lymph.
In conclusion, this hypothesis provides a fundamentally simple explanation for many of the abnormalities believed to be important in 
